Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations (Pediatric MATCH)

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations

  • Clinical Trial Information

    Trial Contact: Spinelli, Jennifer; Armatti, Julie M; Doyle, Katherine M; Dubberly, Paige D; Parker, Melanie

  • IRB No: APEC1621N

    Protocol Abbrev: APEC1621N

    Principal Investigator: Amy A. Smith, MD

    Phase: Drug: Phase II

    Age Group: Adult;Pediatric

    Secondary Protocol No: APEC1621N

    Treatment: Drug: Selpercatinib

    Therapies Involved: Chemotherapy ID: NCT03698994

  • Objective

    To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with selpercatinib (LOXO-292) with advanced solid tumors (including central nervous system [CNS] tumors), lymphomas or histiocytic disorders that harbor activating genetic alterations in the RET pathway.

  • Key Eligibility

    Sexes Eligible for Study - All
    Ages - 12 Months to 21 Years (Child, Adult)
    Accepts Healthy Volunteers - No